Behçet disease

International Ophthalmology Clinics

Volumn 46, Issue 2, 2006, Pages 209-233

  Yates, Paul A ^a   Michelson, Joseph B ^b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b Atlee Gleaton Eye Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; BLOOD CLOTTING FACTOR 5 LEIDEN; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA B51 ANTIGEN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; METHOTREXATE; MICA; PREDNISONE; TACROLIMUS;

APHTHOUS ULCER; ARTERY THROMBOSIS; ARTHRALGIA; BEHCET DISEASE; BONE MARROW SUPPRESSION; CATARACT; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONFERENCE PAPER; DEMENTIA; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG INDUCED CANCER; ENVIRONMENTAL FACTOR; ERYTHEMA NODOSUM; EXTRAPYRAMIDAL SYNDROME; EYE INFECTION; EYE INJURY; FLU LIKE SYNDROME; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENITAL ULCER; GERMANY; HEMOPTYSIS; HLA SYSTEM; HUMAN; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; IMMUNOLOGY; INFERTILITY; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; JAPAN; JOINT SWELLING; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOCYTOSIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MENINGOENCEPHALITIS; MENTAL DISEASE; MOUTH ULCER; NEPHROTOXICITY; NEUROLOGICAL COMPLICATION; NONHUMAN; OSTEOPOROSIS; PARALYSIS; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; PULMONARY HYPERTENSION; RASH; RETINA BLOOD VESSEL OCCLUSION; RETINA DEGENERATION; RETINA EDEMA; RETINA MACULA CYSTOID EDEMA; RETINA VASCULITIS; SECONDARY GLAUCOMA; SEIZURE; SKIN DEFECT; THROMBOPHLEBITIS; TUBERCULOSIS; TURKEY (REPUBLIC); UNITED STATES; UVEITIS; VEIN THROMBOSIS; VENULE; VISUAL IMPAIRMENT;

EID: 33746127940     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-200604620-00017     Document Type: Conference Paper

References (134)

1. Feigenbaum A. Description of Behcet's syndrome in the Hippocratic third book of endemic diseases. Br J Ophthalmol. 1956;40:355-357.
2. Behcet H. Some observations on clinical picture of so-called triple symptom complex. Ann Rheum Dis. 1963;22:26-35.
3. Adamantiades B. Sur un case d'iritis a hypopyon recidivant. Ann Oculist (Paris). 1931;168:271-278.
4. Behcet H. Uber rez idivierende, aphthose, durch ein virus verursachte Geschwure am Munde, am Auge und an Genitalien. Dermatol Wochenschr. 1937;105:1152-1157.
5. Diamond JG, Kaplan HJ. Lensectomy and vitrectomy for complicated cataract secondary to uveitis. Arch Ophthalmol. 1978;96:1798-1804.
6. Oshima Y, et al. Clinical studies on Behcet's syndrome. Ann Rheum Dis. 1963;22:36.
7. Dilsen N, et al. Risk factors for vital organ involvement in Behcet's disease. In: Godeau P, Wechsler B, eds. Behcet's Disease. Paris: Elsevier; 1993:165-169.
8. Sakane T, Takeno M, Suzuki N, et al. Behcet's disease. N Engl J Med. 1999;341:1284-1291.
9. Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behcet disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136:1114-1119.
10. Chajek T, Fainaru M. Behcet's disease. Report of 41 cases and a review of the literature. Medicine (Baltimore). 1975;54:179-196.
11. Kone-Paut I, Geisler I, Wechsler B, et al. Familial aggregation in Behcet's disease: high frequency in siblings and parents of pediatric probands. J Pediatr. 1999;135:89-93.
12. Gul A, Inane M, Ocal L, et al. Familial aggregation of Behcet's disease in Turkey. Ann Rheum Dis. 2000;59:622-625.
13. Imai Y. Studies on prognosis and symptoms of Behcet's disease in long-term observation. Jpn J Clin Ophthalmol. 1971;25:661-694.
14. Mamo JG. The rate of visual loss in Behcet's disease. Arch Ophthalmol. 1970;84:451-452.
15. Michelson JB, Chisari FV. Behcet's disease. Surv Ophthalmol. 1982;26:190-203.
16. Matsuo T, Itami M, Nakagawa H, et al. The incidence and pathology of conjunctival ulceration in Behcet's syndrome. Br J Ophthalmol. 2002;86:140-143.
17. Zamir E, Bodaghi B, Tugal-Tutkun I, et al. Conjunctival ulcers in Behcet's disease. Ophthalmology. 2003;110:1137-1141.
18. Akman-Demir G, Serdaroglu P, Tasci B. Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group. Brain. 1999;122(Pt 11):2171-2182.
19. Kotter I, Gunaydin I, Stubiger N, et al. Comparative analysis of the association of HLA-B*51 suballeles with Behcet's disease in patients of German and Turkish origin. Tissue Antigens. 2001;58:166-170.
20. Mizuki N, Ota M, Katsuyama Y, et al. Sequencing-based typing of HLA-B*51 alleles and the significant association of HLA-B*5101 and -B*5108 with Behcet's disease in Greek patients. Tissue Antigens. 2002;59:118-121.
21. Verity DH, Marr JE, Ohno S, et al. Behcet's disease, the Silk Road and HLA-B51: historical and geographical perspectives. Tissue Antigens. 1999;54:213-220.
22. Ota M, Mizuki N, Katsuyama Y, et al. The critical region for Behcet disease in the human major histocompatibility complex is reduced to a 46-kb segment centromeric of HLA-B, by association analysis using refined microsatellite mapping. Am J Hum Genet. 1999;64:1406-1410.
23. Ahmad T, Wallace GR, James T, et al. Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum. 2003;48:807-813.
24. Mizuki N, Ota M, Kimura M, et al. Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behcet disease. Proc Natl Acad Sci U S A. 1997;94:1298-1303.
25. Wallace GR, Verity DH, Delamine LJ, et al. MIC-A allele profiles and HLA class I associations in Behcet's disease. Immunogenetics. 1999;49:613-617.
26. Mizuki N, Inoko H, Sugimura K, et al. RFLP analysis in the TNF-beta gene and the susceptibility to alloreactive NK cells in Behcet's disease. Invest Ophthalmol Vis Sci. 1992;33:3084-3090.
27. Verity DH, Wallace GR, Vaughan RW, et al. HLA and tumor necrosis factor (TNF) polymorphisms in ocular Behcet's disease. Tissue Antigens. 1999;54:264-272.
28. Sfikakis PP, Theodossiadis PG, Katsiari CG, et al. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet. 2001;358:295-296.
29. Verity DH, Vaughan RW, Madanat W, et al. Factor V Leiden mutation is associated with ocular involvement in Behcet disease. Am J Ophthalmol. 1999;128:352-356.
30. Verity DH, Vaughan RW, Kondeatis E, et al. Intercellular adhesion molecule-1 gene polymorphisms in Behcet's disease. Eur J Immunogenet. 2000;27:73-76.
31. Gul A, Hajeer AH, Worthington J, et al. Linkage mapping of a novel susceptibility locus for Behcet's disease to chromosome 6p22-23. Arthritis Rheum. 2001;44:2693-2696.
32. Hirohata T, Kuratsune M, Nomura A, et al. Prevalence of Behcet's syndrome in Hawaii. With particular reference to the comparison of the Japanese in Hawaii and Japan. Hawaii Med J. 1975;34:244-246.
33. Zouboulis CC, Kotter I, Djawari D, et al. Epidemiological features of Adamantiades-Behcet's disease in Germany and in Europe. Yonsei Med J. 1997;38:411-422.
34. Lehner T. The role of heat shock protein, microbial and autoimmune agents in the aetiology of Behcet's disease. Int Rev Immunol. 1997;14:21-32.
35. Krause I, Monselise Y, Mib G, et al. Anti-saccharomyces cerevisiae antibodies - a novel serologic marker for Behcet's disease. Clin Exp Rheumatol. 2002;20(Suppl 26):S21-S24.
36. Kaneko F, Oyama N, Nishibu A. Streptococcal infection in the pathogenesis of Behcet's disease and clinical effects of minocycline on the disease symptoms. Yonsei Med J. 1997;38:444-454.
37. Lehner T, Lavery E, Smith R, et al. Association between the 65-kilodalton heat shock protein, Streptococcus sanguis, and the corresponding antibodies in Behcet's syndrome. Infect Immun. 1991;59:1434-1441.
38. Isogai E, et al. Detection of antibodies against Borrelia burgdorferi in patients with uveitis. Am J Ophthalmol. 1991;112:23-30.
39. Avci O, Ellidokuz E, Simsek I, et al. Helicobacter pylori and Behcet's disease. Dermatology. 1999;199:140-143.
40. Marquardt JL, Snyderman R, Oppenheim JJ. Depression of lymphocyte transformation and exacerbation of Behcet's syndrome by ingestion of english walnuts. Cell Immunol. 1973;9:263-272.
41. Lehner T Characterization of mucosal antibodies in recurrent aphthous ulceration and Behcet's syndrome. Arch Oral Biol. 1969;14:843-853.
42. Nazzaro P. Cutaneous manifestations of Behcet's disease: clinical and histopathological findings. In: International symposium on Behcet's syndrome, Rome. 1965.
43. Enoch BA, Castillo-Olivares JL, Khoo TC, et al. Major vascular complications in Behcet's syndrome. Postgrad Med J. 1968;44:453-459.
44. Mege JL, Dilsen N, Sanguedolce V, et al. Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. A comparative study with familial Mediterranean fever and healthy subjects. J Rheumatol. 1993;20:1544-1549.
45. Oztas MO, Onder M, Gurer MA, et al. Serum interleukin 18 and tumur necrosis factor-alpha levels are increased in Behcet's disease. Clin Exp Dermatol. 2005;30:61-63.
46. Li B, Yang P, Zhou H, et al. T-bet expression is upregulated in active Behcet's disease. Br J Ophthalmol. 2003;87:1264-1267.
47. Nishida T, Hirayama K, Nakamura S, et al. Proliferative response of CD8+ gamma delta+ T cells to Streptococcus sanguis in patients with Behcet's disease. Ocul Immunol Inflamm. 1998;6:139-144.
48. Bank I, Duvdevani M, Livneh A. Expansion of gammadelta T-cells in Behcet's disease: role of disease activity and microbial flora in oral ulcers. J Lab Clin Med. 2003;141:33-40.
49. Hamzaoui K, Hamzaoui A, Guemira F, et al. Cytokine profile in Behcet's disease patients. Relationship with disease activity. Scand J Rheumatol. 2002;31:205-210.
50. Eksioglu-Demiralp E, Kibaroglu A, Direskeneli H, et al. Phenotypic characteristics of B cells in Behcet's disease: increased activity in B cell subsets. J Rheumatol. 1999;26:826-832.
51. Lehner T. Pathology of recurrent oral ulceration and oral ulceration in Behcet's syndrome: light, electron and fluorescence microscopy. J Pathol. 1969;97:481-494.
52. Rogers RSIII, Sams WMJr, Shorter RG. Lymphocytotoxicity in recurrent aphthous stomatitis. Lymphocytotoxicity for oral epithelial cells in recurrent aphthous stomatitis and Bechet syndrome. Arch Dermatol. 1974;109:361-363.
53. Gupta RC, O'Duffy JD, McDuffie FC, et al. Circulating immune complexes in active Behcet's disease. Clin Exp Immunol. 1978;34:213-218.
54. Shimizu T. Behcet's syndrome-lists of clinical and epidemical statistics. Nippon Rinsho. 1974;32(Spec No):2093-2102.
55. Shimizu T, Ehrlich GE, Inaba G, et al. Behcet disease (Behcet syndrome). Semin Arthritis Rheum. 1979;8:223-260.
56. de Smet MD, Dayan M. Prospective determination of T-cell responses to S-antigen in Behcet's disease patients and controls. Invest Ophthalmol Vis Sci. 2000;41:3480-3484.
57. Demirkesen C, Tuzuner N, Mat C, et al. Clinicopathologic evaluation of nodular cutaneous lesions of Behcet syndrome. Am J Clin Pathol. 2001;116:341-346.
58. Inomata H, Rao N. Behcet's vasculitis: histopathology of early and late stages. In: Third International Symposium on Uveitis, Brussels, 1992.
59. Braun-Falco O, Luderschmidt C, Wolff HH. The sterile Behcet pustule: a typical skin manifestation of the Behcet syndrome. Dtsch Med Wochenschr. 1983;108:820-825.
60. Ergun T, Gurbuz O, Harvell J, et al. The histopathology of pathergy: a chronologic study of skin hyperreactivity in Behcet's disease. Int J Dermatol. 1998;37:929-933.
61. Yokoyama Y, Kono T, Aoki M. Focal proliferative glomerulonephritis with Behcet's syndrome: report of an autopsy case. Ryumachi. 1973;13:281-288.
62. Michelson JB, Chisari FV, Kansu T. Antibodies to oral mucosa in patients with ocular Behcet's disease. Ophthalmology. 1985;92:1277-1281.
63. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335:1078-1080.
64. Ehrlich GC. Intermittent and periodic arthritic syndromes. In: Hollander JL, McCarty D, eds. Arthritis. Lea & Febiger: Philadelphia; 1972:821.
65. Stevens AM, Johnson FC. New eruptive fever associated with stomatitis and ophthalmia. Am J Dis Child. 1922;24:526.
66. Shikano S, Arai Y. Ophthalmology and Behcet's disease - its therapy and prognosis. Nippon Rinsho. 1968;26:31-37.
67. Soy M, Erken E, Konca K, et al. Smoking and Behcet's disease. Clin Rheumatol. 2000;19:508-509.
68. Scheid P, Bohadana A, Martinet Y. Nicotine patches for aphthous ulcers due to Behcet's syndrome. N Engl J Med. 2000;343:1816-1817.
69. Lipschitz B. Uber eine eigenortige Geschwursform des weiblichen Genitales (ulcus vulvae acutum). Arch Dermatol Syphilol. 1963;114:363.
70. Kobayashi T, Matsumaya E, Sugimoto T. Gynecological aspect of mucocutaneous-ocular syndromes. World Obstet Gynecol. 1959;11:995.
71. Strachan RW, Wigzell FW. Polyarthritis in Behcet's multiple symptom complex. Ann Rheum Dis. 1963;22:26-35.
72. Mason RM, Barnes CG. Behcet's syndrome with arthritis. Ann Rheum Dis. 1969;28:95-103.
73. Bernhard GC, Heim LR. Transfer factor treatment of Behcet's syndrome. J Rheumatol. 1974;1:34.
74. Wolf RE, Fudenberg HH, Welch TM, et al. Treatment of Bechcet's syndrome with transfer factor. JAMA. 1977;238:869-871.
75. Chajek T, Fainaru M. Behcet's disease with decreased fibrinolysis and superior vena caval occlusion. Br Med J. 1973;1:782-783.
76. Kalbian VV, Challis MT. Behcet's disease. Report of twelve cases with three manifesting as papilledema. Am J Med. 1970;49:823-829.
77. Masheter HC. Behcet's syndrome complicated by intracranial thrombophlebitis. Proc R Soc Med. 1959;52:1039-1040.
78. Sugioka Y, Ohe H, Tanaka T. Two cases of hip joint deformation associated with Behcet's syndrome. Orthop Surg Traumatol. 1966;15:131.
79. Hills EA. Behcet's syndrome with aortic aneurysms. Br Med J. 1967;4:152-154.
80. Shikano S. Ocular pathology of Behcet's syndrome. In: International symposium on Behcet's syndrome, Rome, 1965.
81. Enoch BA. Gangrene in Behcet's syndrome. Br Med J. 1969;3:54.
82. Movioglu H. Behcet's recurrent disease: analytical review of the literature. Missouri Med. 1958;55:1209.
83. Shimizu T, Ogino T. Clinico-pathological studies on the intestinal lesions in Behcet's disease with special reference to entero-Behcet's syndrome. Stomach Intestine. 1975;10:1593.
84. Shimizu T, Saito Y. Behcet's syndrome. Clin Sci. 1971;7:451.
85. Petty TL, Scoggin CH, Good JT. Recurrent pneumonia in Behcet's syndrome: roentgenographic documentation during 13 years. JAMA. 1969;238:2529.
86. Davies JD. Behcet's syndrome with haemoptysis and pulmonary lesions. J Pathol. 1973;109:351-356.
87. Shimizu T. Behcet's disease, in Rheumatology. Tokyo: Igaku Publishers; 1976:402.
88. Nestor G, Beroniade V, Carnaru S, et al. Behcet's disease with renal involvement (with reference to three anatomico-clinical cases). Rom Med Rev. 1970;14:27-32.
89. Bietti GB, Bruna R. An ophthalmic report on Behcet's disease. In: International Symposium on Behcet's Disease. Basel: S. Karger; 1965.
90. Cavora V, D'Ermo F. A case of neuro-Behcet's syndrome. XVII Concilium Ophthal Acta (Canada and USA). 1954;3:1489.
91. O'Duffy JD, Goldstein NP. Neurologic involvement in seven patients with Behcet's disease. Am J Med. 1976;61:170-178.
92. Shimizu T, Inaba G. Epidemiological studies on Behcet's disease in Japan. J Jpn Rheum Assoc. 1976;16:224.
93. Monastero R, Camarda C, Pipia C, et al. Cognitive impairment in Behcet's disease patients without overt neurological involvement. J Neurol Sci. 2004;220:99-104.
94. Pallis CA, Fudge BJ. The neurological complications of Behcet's syndrome. AMA Arch Neurol Psychiatry. 1956;75:1-14.
95. Siva A, Altintas A, Saip S. Behcet's syndrome and the nervous system. Curr Opin Neurol. 2004;17:347-357.
96. Muhaya M, Lightman S, Ikeda E, et al. Behcet's disease in Japan and in Great Britain: a comparative study. Ocul Immunol Inflamm. 2000;8:141-148.
97. Michelson JB, Michelson PE, Chisari FV. Subretinal neovascular membrane and disciform scar in Behcet's disease. Am J Ophthalmol. 1980;90:182-185.
98. Elgin U, Berker N, Batman A. Incidence of secondary glaucoma in behcet disease. J Glaucoma. 2004;13:441-444.
99. Green WR, Bon Sool K. Behcet's disease. A report of the ocular histopathology of one case. Surv Ophthalmol. 1967;12:324-332.
100. Okada AA. Drug therapy in Behcet's disease. Ocul Immunol Inflamm. 2000;8:85-91.
101. Reed JB, Morse LS, Schwab IR. High-dose intravenous pulse methylprednisolone hemisuccinate in acute Behcet retinitis. Am J Ophthalmol. 1998;125:409-411.
102. Karacorlu M, Mudun B, Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol. 2004;138:289-291.
103. Kaklamani VG, Kaklamanis PG. Treatment of Behcet's disease - an update. Semin Arthritis Rheum. 2001;30:299-312.
104. Whitcup SM, Salvo EC Jr, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol. 1994;118:39-45.
105. Binder AI, Graham EM, Sanders MD, et al. Cyclosporin A in the treatment of severe Behcet's uveitis. Br J Rheumatol. 1987;26:285-291.
106. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet. 1989;1:1093-1096.
107. Ishioka M, Ohno S, Nakamura S, et al. FK506 treatment of noninfectious uveitis. Am J Ophthalmol. 1994;118:723-729.
108. Sloper CM, Powell RJ, Dua HS. Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology. 1999;106:723-728.
109. de Smet MD, Rubin BI, Whiteup SM, et al. Combined use of cyclosporine and ketoconazole in the treatment of endogenous uveitis. Am J Ophthalmol. 1992;113:687-690.
110. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy. Ophthalmology. 1999;106:586-589.
111. Ozyazgan Y, Yurdakul S, Yaziei H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br J Ophthalmol. 1992;76:241-243.
112. Kotter I, Durk H, Saal J, et al. Therapy of Behcet's disease. Ger J Ophthalmol. 1996;5:92-97.
113. Yazici H, Pazarli H, Barnes CG, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281-285.
114. Hamuryudan V, Ozyazgan Y, Hizli N, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769-774.
115. Mamo JG, Azzam SA. Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol. 1970;84:446-450.
116. Kotter I, Zierhut M, Eckstein AK, et al. Human recombinant Interferon alfa-2a for the treatment of Behcet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003;87:423-431.
117. Alpsoy E, Durusoy C, Yilmaz E, et al. Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol. 2002;138:467-471.
118. O'Duffy JD, Calamia K, Cohen S, et al. Interferon-alpha treatment of Behcet's disease. J Rheumatol. 1998;25:1938-1944.
119. Joseph A, Raj D, Dua HS, et al. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology. 2003;110:1449-1453.
120. Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al. Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet. 2001;358:1644.
121. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
122. Triolo G, Vadala M, Accardo-Palumbo A, et al. Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis. 2002;61:560-561.
123. Wechsler B, Sable-Fourtassou R, Bodaghi B, et al. Infliximab in refractory uveitis due to Behcet's disease. Clin Exp Rheumatol. 2004;22(4 Suppl 34):S14-S16.
124. Sfikakis PP, Kaklamanis PH, Elezogiou A, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med. 2004;140:404-406.
125. Licata G, Pinto A, Tuttolomondo A, et al. Anti-tumor necrosis factor alpha monoclonal antibody therapy for recalcitrant cerebral vasculitis in a patient with Behcet's syndrome. Ann Rheum Dis. 2003;62:280-281.
126. Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet's syndrome with infliximab. Rheumatology (Oxford). 2001;40:473-474.
127. Eklund KK, Peltomaa R, Leirisalo-Repo M. Occurrence of pulmonary thromboembolism during infliximab therapy. Clin Exp Rheumatol. 2003;21:679.
128. Puli SR, Benage DD. Retinal vein thrombosis after infliximab (Remicade) treatment for Crohn's disease. Am J Gastroenterol. 2003;98:939-940.
129. Cambien B, Bergmeier W, Saffaripour S, et al. Antithrombotic activity of TNF-alpha. J Clin Invest. 2003;112:1589-1596.
130. Ozerturk Y, Bardak Y, Durmus M. Vitreoretinal surgery in Behcet's disease with severe ocular complications. Acta Ophthalmol Scand. 2001;79:192-196.
131. Soylu M, Demircan N, Pelit A. Pars plana vitrectomy in ocular Behcet's disease. Int Ophthalmol. 2001;24:219-223.
132. Berker N, Soykan E, Elgin U, et al. Phacoemulsification cataract extraction and intraocular lens implantation in patients with Behcet's disease. Ophthalmic Surg Lasers Imag. 2004;35:215-218.
133. Kadayifcilar S, Gedik S, Eldem B, et al. Cataract surgery in patients with Behcet's disease. J Cataract Refract Surg. 2002;28:316-320.
134. Yoshida A, Kawashima H, Motoyama Y, et al. Comparison of patients with Behcet's disease in the 1980s and 1990s. Ophthalmology. 2004;111:810-815.